Is OCUL or OMER more undervalued in 2026?

CirclFi compares Ocular Therapeutix, Inc. (OCUL) and Omeros Corporation (OMER) using 13 institutional-grade valuation models. OCUL has a Quality of Company score of 7.2/10 while OMER scores 3.3/10.

Which is a better buy — OCUL or OMER?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OCUL and OMER valuations compare?

OCUL at $9.15 and OMER at $11.15 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OCUL vs OMER Valuation Comparison 2026 — Intrinsic Value Analysis

OCUL

Biotechnology

Ocular Therapeutix, Inc.

Quality

7.2

out of 10

Value Trap

SAFE

Price

$9.15

Last close

Models

11/13

Active

OMER

Biotechnology

Omeros Corporation

Quality

3.3

out of 10

Value Trap

LOW

Price

$11.15

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	OCUL Fair Value	OCUL Upside	OMER Fair Value	OMER Upside
Bayesian DCF	Intrinsic	$4.28	-53.2%	$2.45	-78.0%
Earnings Power Value	Intrinsic	$2.78	-70.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.65	-60.1%	$3.03	-72.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OCUL vs OMER — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OCUL vs OMER — Which Stock Is More Undervalued?

OCUL scores higher with a 7.2/10 quality rating vs OMER's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ocular Therapeutix, Inc. (OCUL) and Omeros Corporation (OMER) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OCUL currently trades at $9.15 with a QOC of 7.2/10, while OMER trades at $11.15 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).